We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merger Expected to Close Today 80% of Shares Tendered Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (βTevaβ) today announced the successful completion of the tender offer (the...
Among the companies with shares expected to actively trade in Tuesday's session are Delta Air Lines Inc. (DAL), NuPathe Inc. (PATH) and YRC Worldwide Inc. (YRCW). Delta Air Lines said its...
Endo Merger Agreement with NuPathe Terminated -- Endo congratulates NuPathe on negotiating an improved agreement with Teva and accepts termination fee PR Newswire MALVERN, Pa., Jan. 21, 2014...
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq:PATH) for $3.65 per share...
NuPathe Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover PR Newswire DALLAS, Jan. 17, 2014 DALLAS, Jan. 17, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons...
Among the companies with shares expected to actively trade in Wednesday's session are Container Store Group Inc. (TCS), J.C. Penney Co. (JCP) and NuPathe Inc. (PATH). Apollo Education Group Inc.'s...
Lifshitz Law Firm Announces Investigation of Coleman Cable, Inc., NuPathe Inc., Solta Medical, Inc., The Jones Group Inc. and Tufco Technologies, Inc. PR Newswire NEW YORK, Dec. 30, 2013 NEW...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NuPathe, Inc. Juan E. Monteverde, a partner at...
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of NUPATHE INC. and Its Board of Directors In Connection with the Sale of the Company to Endo Health Solutions -- PATH PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions